1. Home
  2. ALDX

as of 11-28-2025 12:37pm EST

$5.51
$0.08
-1.52%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Chart Type:
Time Range:
Founded: 2004 Country:
United States
United States
Employees: N/A City: LEXINGTON
Market Cap: 336.3M IPO Year: 2014
Target Price: $9.50 AVG Volume (30 days): 722.4K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.72 EPS Growth: N/A
52 Week Low/High: $1.14 - $7.20 Next Earning Date: 11-05-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 63.48%

AI-Powered ALDX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 68.24%
68.24%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: